Drug intelligence / Profile preview

Qinhuang Formula

Development stage: Unknown
Lead developer: Ruijin Hospital
Administration: Oral

Overview

Qinhuang Formula is a Traditional Chinese Medicine (TCM) herbal preparation developed by Ruijin Hospital (Shanghai Jiao Tong University School of Medicine) for the treatment of hematological malignancies, particularly diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). It is primarily utilized as a maintenance therapy following standard chemotherapy (such as R-CHOP) to improve disease-free survival and reduce recurrence in elderly patients. The formula typically consists of several herbal components, including *Radix Astragali* (Huang Qi) and *Radix Scutellariae* (Huang Qin), which are thought to exert anti-tumor effects through immune modulation, induction of apoptosis in malignant B cells, and inhibition of tumor cell proliferation.

Other names: Qinhuang Fang秦黄方

Beyond the preview

Go deeper on Qinhuang Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qinhuang Formula.

Explore the full profile